The Federal Joint Committee (G-BA) reviews all clinical evidence and real-world data to determine whether a new GLP-1 drug offers advantages over existing treatments for diabetes and obesity
Similar content being viewed by others Introduction (L.N
L.KimK.-W.et al (2020)
However, the primary pathway for glutahionylation and its reversal involves enzymes of the glutathione S-transferase family and glutaredoxin
Serving Size: 15g
Investigators are developing models to predict the efficacy of DPP-4 inhibitors, GLP-1 RAs, SGLT-2 inhibitors, sulfonylureas, and thiazolidinediones to lower HbA1c levels using widely available clinical features (age, duration of diabetes, sex, baseline HbA1c, BMI, estimated glomerular filtration rate, HDL cholesterol, total cholesterol, and alanine aminotransferase) to facilitate therapy (14)